PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34998176-7	2022	Prevention of premature initiation of end-resection, by combining Chk2 inhibition with IR or carboplatin treatment, successfully sensitized IR and platinum-resistant Wwox-deficient cells by synthetic lethality, but did not alter response of Wwox-sufficient cells.	Platinum	147-155	checkpoint kinase 2	Homo sapiens	66-70	
27905519-3	2016	We here report the retrospective analysis of polymorphisms in 5 genes (ATM, ATR, Chk1, Chk2 and CDK12) involved in the cellular response to platinum in a cohort of 240 cancer patients with late stage ovarian cancer.	Platinum	140-148	checkpoint kinase 2	Homo sapiens	87-91	
33827148-7	2021	DNA damage response and apoptosis including the relationship between FOXOs and ATM-Chk2-p53 are essential for platinum resistance of ovarian cancer.	Platinum	110-118	checkpoint kinase 2	Homo sapiens	83-87	
24657486-0	2014	Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer.	Platinum	51-59	checkpoint kinase 2	Homo sapiens	0-19	
24657486-0	2014	Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer.	Platinum	51-59	checkpoint kinase 2	Homo sapiens	21-25	
24657486-10	2014	CONCLUSIONS: Chk2 is related to good response to platinum-based chemotherapy in advanced stage HGSOC patients.	Platinum	49-57	checkpoint kinase 2	Homo sapiens	13-17	
24657486-11	2014	Chk2-depleted ovarian cancer cell lines have diminished platinum sensitivity, suggesting that Chk2 should not be considered a therapeutic target along with platinum-based treatment in HGSOC patients.	Platinum	56-64	checkpoint kinase 2	Homo sapiens	0-4	
22312557-0	2011	The Role of Wild-Type p53 in Cisplatin-Induced Chk2 Phosphorylation and the Inhibition of Platinum Resistance with a Chk2 Inhibitor.	Platinum	90-98	checkpoint kinase 2	Homo sapiens	117-121	
22312557-12	2011	Our findings suggest that inhibition of platinum resistance can be achieved with a small-molecule inhibitor of Chk2, thus improving the therapeutic indices for platinum chemotherapy.	Platinum	40-48	checkpoint kinase 2	Homo sapiens	111-115	
22312557-12	2011	Our findings suggest that inhibition of platinum resistance can be achieved with a small-molecule inhibitor of Chk2, thus improving the therapeutic indices for platinum chemotherapy.	Platinum	160-168	checkpoint kinase 2	Homo sapiens	111-115	
27747004-0	2016	Association of CHEK2 polymorphisms with the efficacy of platinum-based chemotherapy for advanced non-small-cell lung cancer in Chinese never-smoking women.	Platinum	56-64	checkpoint kinase 2	Homo sapiens	15-20	
27747004-3	2016	This study aimed to investigate the relationship between polymorphisms in the CHEK2 gene and efficacy of platinum-based doublet chemotherapy in never-smoking Chinese female patients with advanced non-small-cell lung cancer (NSCLC).	Platinum	105-113	checkpoint kinase 2	Homo sapiens	78-83	
27747004-4	2016	METHODS: Using DNA from blood samples of 272 Chinese advanced NSCLC non-smoking female patients treated with first-line platinum-based chemotherapy, we have analyzed the relationships between four SNPs in the CHEK2 gene and clinical outcomes.	Platinum	120-128	checkpoint kinase 2	Homo sapiens	209-214	
27747004-9	2016	CONCLUSIONS: Our findings indicate that SNPs in CHEK2 are related to Chinese advanced NSCLC never-smoking female patients receiving platinum-based doublet chemotherapy in China.	Platinum	132-140	checkpoint kinase 2	Homo sapiens	48-53	
22905093-8	2012	Proteins and genes related to DNA damage response, elongation and telomere extension and repair related directly and indirectly to platinum resistance were overexpressed, as the CHK1 protein and the genes CHEK2, LIG3, POLD1, POLA2, FANCD2, PRPF19, RECQ5 respectively, the last two not previously described in mesothelioma.	Platinum	131-139	checkpoint kinase 2	Homo sapiens	205-210